Comparison of Levosimendan versus Dobutamine in Patients with Moderate to Severe Left Ventricular Dysfunction Undergoing Off-pump Coronary Artery Bypass Grafting: A Randomized Prospective Study

Annals of Cardiac Anaesthesia

Volumn 20, Issue 2, 2017, Pages 200-206

  Kandasamy, Ashok ^a   Simon, Hariharan Antony ^a   Murthy, P ^a   Annadurai, Mahalakshmi ^a   Ali, Mushkath Mohamed ^a   Ramanathan, Gayathri ^a  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Cardiac index; dobutamine; Intensive Care Unit stay; levosimendan; mixed venous oximetry; stroke work index

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ETOMIDATE; FENTANYL; LACTIC ACID; LEVOSIMENDAN; MIDAZOLAM; PANTOPRAZOLE; SEVOFLURANE; VECURONIUM; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; AGED; ANESTHESIOLOGICAL PROCEDURE; ARTICLE; ATRIAL FIBRILLATION; BEDTIME DOSAGE; CARDIOVASCULAR PARAMETERS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HOSPITALIZATION; HUMAN; LACTATE BLOOD LEVEL; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORNING DOSAGE; OFF PUMP CORONARY SURGERY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SEVERITY OF ILLNESS INDEX; SURGERY;

ADULT; AGED; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS, OFF-PUMP; DOBUTAMINE; FEMALE; HEMODYNAMICS; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PYRIDAZINES; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85018765329     PISSN: 09719784     EISSN: 09745181     Source Type: Journal    
DOI: 10.4103/aca.ACA_195_16     Document Type: Article

References (27)

1. Groban L, Butterworth J. Perioperative management of chronic heart failure. Anesth Analg 2006;103:557-75.
2. Bouchart F, Tabley A, Litzler PY, Haas-Hubscher C, Bessou JP, Soyer R. Myocardial revascularization in patients with severe ischemic left ventricular dysfunction. Long term follow-up in 141 patients. Eur J Cardiothorac Surg 2001;20:1157-62.
3. Raja SG, Rayen BS. Levosimendan in cardiac surgery: Current best available evidence. Ann Thorac Surg 2006;81:1536-46.
4. Ascione R, Narayan P, Rogers CA, Lim KH, Capoun R, Angelini GD. Early and midterm clinical outcome in patients with severe left ventricular dysfunction undergoing coronary artery surgery. Ann Thorac Surg 2003;76:793-9.
5. Carr JA, Haithcock BE, Paone G, Bernabei AF, Silverman NA. Long-term outcome after coronary artery bypass grafting in patients with severe left ventricular dysfunction. Ann Thorac Surg 2002;74:1531-6.
6. Mathison M, Edgerton JR, Horswell JL, Akin JJ, Mack MJ. Analysis of hemodynamic changes during beating heart surgical procedures. Ann Thorac Surg 2000;70:1355-60.
7. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, et al. Acute myocardial dysfunction and recovery: A common occurrence after coronary bypass surgery. J Am Coll Cardiol 1990;15:1261-9.
8. Chatterjee K, Wolfe CL, DeMarco T. Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful? Cardiol Clin 1994;12:63-72.
9. Cody RJ. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction. J Am Coll Cardiol 1988;12:559-61.
10. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82 2 Suppl: I12-25.
11. Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: Interaction of levosimendan, a calcium sensitiser, with cardiac troponin C. Mol Cell Biochem 2004;266:87-107.
12. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: Preclinical and clinical evidence. J Cardiovasc Pharmacol 2007;50:257-63.
13. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002;360:196-202.
14. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-31.
15. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007;297:1883-91.
16. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82.
17. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
18. Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: Alteration of force-frequency and relaxation-frequency relationships. Circulation 2007;115:1218-24.
19. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102-6.
20. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222-7.
21. Meyer K, Klocke RC, Schipke JD, Gams E, Korbmacher B. Ca2+ sensitizer superior to catecholamine during myocardial stunning? Eur J Cardiothorac Surg 2008;34:326-31.
22. Dernellis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: A combined hemodynamic and Doppler echocardiographic study. Chest 2005;128:2633-9.
23. Robert H, Victor H, Ricardo L, Rajendra M, Robert H, John A. Levosimendan reduces mortality in patients with reduced ejection fraction undergoing cardiac surgery: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2012;59:959-68.
24. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-12.
25. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, et al. The Ca2 -sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-7.
26. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009;102:198-204.
27. Lim JY, Deo SV, Rababa'h A, Altarabsheh SE, Cho YH, Hang D, et al. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: A systematic review and meta-analysis. J Card Surg 2015;30:547-54.